Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells

In this study, we explore the hypothesis that enhanced production of lactate by tumor cells, because of high glycolytic activity, results in inhibition of host immune response to tumor cells. Lactate dehydrogenase-A (LDH-A), responsible for conversion of pyruvate to lactate, is highly expressed in tumor cells. Lentiviral vector–mediated LDH-A short hairpin RNA knockdown Pan02 pancreatic cancer cells injected in C57BL/6 mice developed smaller tumors than mice injected with Pan02 cells. A decrease occurred in the frequency of myeloid-derived suppressor cells (MDSCs) in the spleens of mice carrying LDH-A–depleted tumors. NK cells from LDH-A–depleted tumors had improved cytolytic function. Exogenous lactate increased the frequency of MDSCs generated from mouse bone marrow cells with GM-CSF and IL-6 in vitro. Lactate pretreatment of NK cells in vitro inhibited cytolytic function of both human and mouse NK cells. This reduction of NK cytotoxic activity was accompanied by lower expression of perforin and granzyme in NK cells. The expression of NKp46 was decreased in lactate-treated NK cells. These studies strongly suggest that tumor-derived lactate inhibits NK cell function via direct inhibition of cytolytic function as well as indirectly by increasing the numbers of MDSCs that inhibit NK cytotoxicity. Depletion of glucose levels using a ketogenic diet to lower lactate production by glycolytic tumors resulted in smaller tumors, decreased MDSC frequency, and improved antitumor immune response. These studies provide evidence for an immunosuppressive role of tumor-derived lactate in inhibiting innate immune response against developing tumors via regulation of MDSC and NK cell activity.

[1]  A. Mackensen,et al.  Tumor metabolism as modulator of immune response and tumor progression. , 2012, Seminars in cancer biology.

[2]  Bin Hu,et al.  Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activation , 2012, International journal of cancer.

[3]  T. Seyfried,et al.  Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? , 2012, Epilepsy Research.

[4]  P. Sinha,et al.  Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC) , 2012, Cancer Immunology, Immunotherapy.

[5]  J. Olefsky,et al.  The cellular and signaling networks linking the immune system and metabolism in disease , 2012, Nature Medicine.

[6]  J. Koutcher,et al.  Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. , 2012, Experimental cell research.

[7]  M. Manns,et al.  Myeloid derived suppressor cells in human diseases. , 2011, International immunopharmacology.

[8]  M. Manns,et al.  Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. , 2011, Blood.

[9]  V. Bronte,et al.  Transcription factors in myeloid-derived suppressor cell recruitment and function. , 2011, Current opinion in immunology.

[10]  J. Rathmell,et al.  Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.

[11]  A. Chawla,et al.  Alternative macrophage activation and metabolism. , 2011, Annual review of pathology.

[12]  D. Mathis,et al.  Immunometabolism: an emerging frontier , 2011, Nature Reviews Immunology.

[13]  R. Lenkinski,et al.  On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. , 2011, Neoplasia.

[14]  D. Gabrilovich,et al.  Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.

[15]  S. Bicciato,et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.

[16]  L. Cantley,et al.  Altered metabolism in cancer , 2010, BMC Biology.

[17]  V. Bronte,et al.  Myeloid-derived suppressor cell heterogeneity and subset definition. , 2010, Current opinion in immunology.

[18]  W. Linehan,et al.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.

[19]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[20]  I. Borrello,et al.  Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.

[21]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[22]  H. Shime,et al.  Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway1 , 2008, The Journal of Immunology.

[23]  A. Mackensen,et al.  Tumor-induced modulation of dendritic cell function. , 2008, Cytokine & growth factor reviews.

[24]  S. Pizzo,et al.  Carbohydrate restriction, prostate cancer growth, and the insulin‐like growth factor axis , 2008, The Prostate.

[25]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[26]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[27]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[28]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[29]  M. Kiebish,et al.  The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer , 2007, Nutrition & metabolism.

[30]  P. Dahm,et al.  Reversal of Tumor-Mediated Immunosuppression , 2007, Clinical Cancer Research.

[31]  B. Han,et al.  Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? , 2006, Cancer and Metastasis Reviews.

[32]  A. Mackensen,et al.  Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. , 2006, Blood.

[33]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[34]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[35]  M. Dewhirst,et al.  Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[36]  W. Kreutz,et al.  Acidic pH inhibits non-MHC-restricted killer cell functions. , 2000, Clinical immunology.

[37]  H. Lyng,et al.  Correlation of high lactate levels in head and neck tumors with incidence of metastasis. , 1997, The American journal of pathology.

[38]  E. Podack,et al.  Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. , 1996, Journal of immunology.

[39]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[40]  M. Young,et al.  Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. , 1987, Cancer research.

[41]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .